WJCD  Vol.8 No.2 , February 2018
A Case Report of Cardiac Amyloidosis Presenting with Chest Discomfort
Introduction: Cardiac amyloidosis is one of the several systemic manifestations of amyloidosis. It is a relatively uncommon disease. Patients with cardiac amyloidosis clinically present with rapidly progressive heart failure. Case Presentation: We present a case of 64-year-old man with multiple episodes of chest discomfort accompanied sometimes with dyspnoea for the past several months. A non-specific ST-T changes with low voltage limb leads on ECG, a diastolic dysfunction with preserved ejection fraction on echocardiography, increased troponin and BNP, increased serum λ/κ light chain ratio led us to highly suspect amyloidosis with cardiac involvement. Abdominal fat pad biopsy confirmed the amyloid type change of subcutaneous fat, with immunohistochemistry revealing Lambda positive. After confirmed diagnosis of primary systemic amyloidosis with cardiac involvement, patient completed six cycles of chemotherapy with bortezomib and dexamethasone. The patient showed significant improvements after chemotherapy and supportive therapy. Conclusion: Amyloidosis is relatively fatal disease. Patients often have a short life expectancy after symptom onset. Early diagnosis is crucial to proper management and better prognosis.
Cite this paper
Adhikari, B. , Wang, Y. , Li, B. , Liu, Q. and Zhang, W. (2018) A Case Report of Cardiac Amyloidosis Presenting with Chest Discomfort. World Journal of Cardiovascular Diseases, 8, 162-168. doi: 10.4236/wjcd.2018.82016.
[1]   Halwani, O. and Delgado, D.H. (2010) Cardiac Amyloidosis: An Approach to Diagnosis and Management. Expert Review of Cardiovascular Therapy, 8, 1007-1013.

[2]   Kappor, P., Thenappan, T., Singh, E., Kumar, S. and Greipp, P.R. (2011) Cardiac Amyloidosis; A Practical Approach to Diagnosis and Management. The American Journal of Medicine, 124, 1006-1015.

[3]   Mohty, D., Damy, T., Cosnay, P., Echahidi, N., Casset, S.D., Virot, P. and Jaccard, A. (2013) Cardiac Amyloidosis: Updates in Diagnosis and Management. Archives of Cardiovascular Disease, 106, 528-540.

[4]   Crotty, T.B., Li, C.Y., Edwards, W.D. and Suman, V.J. (1995) Amyloidosis and Endomyocardial Biopsy: Correlation and Extent and Pattern of Deposition with Amyloid Immunophenotype in 100 Cases. Cardiovascular Pathology, 4, 39-42.

[5]   Desai, H.V., Aronow, W.S., Peterson, S.J. and Frishman, W.H. (2010) Cardiac Amyloidosis: Approaches to Diagnosis and Management. Cardiology in Review, 18, 1-11.

[6]   Falk, R.H, Alexander, K.M, Liao, R. and Dorbala, S. (2016) AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. Journal of the American College of Cardiology, 68, 1323-1341.

[7]   Sanchorawala, V. (2006) Light-Chain (AL) Amyloidosis: Diagnosis and Treatment. Clinical Journal of the American Society of Nephrology, 1, 1331-1341.

[8]   Anish, G. and Brain, M.C. (2015) Cardiac Amyloidosis Presenting as Recurrent Acute Coronary Syndrome with Unobstructed Coronary Arteries: Case Report. Indian Heart Journal, 67, 570-573.

[9]   Masafumi, O. and Shigeru, K. (2018) Dysphagia due to Systemic Light Chain Amyloidosis revealed by Videoendoscopic and Videofluorosgraphic Swallowing Examinations. Otolaryngology Case Reports, 6, 406.

[10]   Rapezzi, C., Quarta, C.C., Riva, L., Longhi, S., Gallelli, I., Lorenzini, M., et al. (2010) Transthyretin-Related Amyloidosis and the Heart: A Clinical Overview. Nature Reviews Cardiology, 7, 398-408.

[11]   Maceira, A.M., Joshi, J., Prasad, S.K., Moon, J.C., Perugini, E., Harding, I., et al. (2005) Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation, 111, 186-193.

[12]   Dispenzieri, A., Gertz, M.A., Kyle, R.A., Lacy, M.Q., Burritt, M.F., Therneau, T.M., et al. (2004) Serum Cardiac Troponins and N-Terminal pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis. Journal of Clinical Oncology, 22, 3751-3757.

[13]   Gertz, M.A., Comenzo, R., Falk, R.H., Fermand, J.P., Hazenberg, B.P., Hawkins, P.N., et al. (2005) Definition of Organ Involvement and Treatment Response in Immunoglobulin Light Chain Amyloidosis (AL): A Consensus Opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April. American Journal of Hematology, 79, 319-328.

[14]   Cristina, C.Q., Jenna, L.K. and Rodney, H.F. (2012) Cardiac Amyloidosis. Circulation, 126, e178-e182.

[15]   Selvanayagam, J.B., Hawkins, P.N., Paul, B., Myerson, S.G. and Neubauer, S. (2007) Evaluation and Management of the Cardiac Amyloidosis. Journal of the American College of Cardiology, 50, 2101-2110.

[16]   Gertz, M.A. (2011) Immunoglobulin Light Chain Amyloidosis: 2011 Update on Diagnosis, Risk Stratification, and Management. American Journal of Hematology, 86, 181-186.

[17]   Munjewar, C., Agrawal, R. and Sharma, S. (2014) Cardiac Amyloidosis: A Report of Two Cases. Indian Heart Journal, 66, 473-476.